Sitagliptin Results in a Decrease of Truncated Apolipoprotein C1

Nicole E.B. Skinner, Matthew S. Wroblewski, Julie A. Kirihara, Gary L. Nelsestuen, Elizabeth R. Seaquist

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Apolipoprotein C1 (ApoC1) is a component of multiple lipoproteins where it performs a variety of roles in lipid metabolism and transport. ApoC1 exists as both full-length and truncated isoforms. Truncation of ApoC1 has been postulated to result from the action of dipeptidyl peptidase-4 (DPP-4), the target of a new class of diabetes drugs that includes sitagliptin phosphate. In this study, we sought to determine if oral administration of sitagliptin altered the proportion of ApoC1 isoforms circulating in humans. Results indicated a dramatic change in ApoC1 truncation, consistent with a high level of DPP-4 inhibition by sitagliptin. Funding: University of Minnesota, Minneapolis, MN, USA.

Original languageEnglish (US)
Pages (from-to)395-401
Number of pages7
JournalDiabetes Therapy
Issue number3
StatePublished - Sep 26 2015

Bibliographical note

Publisher Copyright:
© 2015, The Author(s).


  • Apolipoprotein C1
  • Mass spectrometry
  • Sitagliptin


Dive into the research topics of 'Sitagliptin Results in a Decrease of Truncated Apolipoprotein C1'. Together they form a unique fingerprint.

Cite this